BAP1 (Ubiquitin carboxyl-terminal hydrolase BAP1) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Mesothelioma, Biliary tract cancer and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Deubiquitinating enzyme that plays a key role in chromatin by mediating deubiquitination of histone H2A and HCFC1. Catalytic component of the polycomb repressive deubiquitinase (PR-DUB) complex, a complex that specifically mediates deubiquitination of histone H2A monoubiquitinated at 'Lys-120' (H2AK119ub1). Does not deubiquitinate monoubiquitinated histone H2B. The PR-DUB complex is an epigenetic regulator of gene expression and acts as a transcriptional coactivator, affecting genes involved in development, cell communication, signalling, cell proliferation and cell viability. Antagonises PRC1 mediated H2AK119ub1 monoubiquitination. As part of the PR-DUB complex, associates with chromatin enriched in histone marks H3K4me1, H3K4me3, and H3K27Ac, but not in H3K27me3. Location: Cytoplasm; Nucleus; Chromosome (UniProt). Locus 3p21.1 (HGNC).
- Renal cell carcinoma: Open Targets association 0.68 with renal cell carcinoma (MONDO_0005086); CIViC evidence names this disease
- Mesothelioma: Open Targets association 0.68 with malignant mesothelioma (MONDO_0006292); CIViC evidence names this disease
- Biliary tract cancer: Open Targets association 0.64 with biliary tract cancer (MONDO_0003060)
- Hepatocellular carcinoma: Open Targets association 0.53 with hepatocellular carcinoma (MONDO_0007256); IntOGen driver in 3 cohorts (HCC)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.54 with gastric cancer (MONDO_0001056); IntOGen driver in 1 cohort (STAD)
- Breast cancer: IntOGen driver in 1 cohort (BRCA)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"BAP1" OR ABSTRACT:"BAP1" OR TITLE:"BRCA1 associated deubiquitinase 1" OR ABSTRACT:"BRCA1 associated deubiquitinase 1" OR TITLE:"Ubiquitin carboxyl-terminal hydrolase BAP1" OR ABSTRACT:"Ubiquitin carboxyl-terminal hydrolase BAP1" OR TITLE:"hucep-6" OR ABSTRACT:"hucep-6" OR TITLE:"KIAA0272" OR ABSTRACT:"KIAA0272" OR TITLE:"UCHL2" OR ABSTRACT:"UCHL2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BAP1, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/bap1.json. Licence CC BY-NC 4.0.